King-Jones Heidy
Known title: See RemarksCIK: 0001794898
Associated companies
Transaction History
| SYRE | ▲ Buy | Option Exercise | 28,933 | $420K | 10/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 400 | $36K | 10/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 16,605 | $1.5M | 10/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 7,228 | $660K | 10/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 2,100 | $195K | 10/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 2,600 | $243K | 10/1/2026 | View on chart |
| SYRE | ▲ Buy | Option Exercise | 400 | $6K | 9/2/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 400 | $36K | 9/2/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 400 | $36K | 9/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 16,548 | $1.4M | 9/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 4,845 | $419K | 9/1/2026 | View on chart |
| SYRE | ▲ Buy | Option Exercise | 27,999 | $406K | 9/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 6,206 | $547K | 9/1/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Spyre Therapeutics Launches $350M Public Offering, Stock Drops
Spyre Therapeutics has priced a $350 million public offering of common stock, which led to a decline in the share price on the launch day. The company also announced inducement awards to support its growth. Analysts from JP Morgan and BTIG have begun coverage, citing a target price around $110 to $121. The offering and analyst interest may influence the stock’s short‑term trajectory.
Spyre Therapeutics Launches $350M Public Offering, Stock Drops. Spyre Therapeutics has priced a $350 million public offering of common stock, which led to a decline in the share price on the launch day. The company also announced inducement awards to support its growth. Analysts from JP Morgan and BTIG have begun coverage, citing a target price around $110 to $121. The offering and analyst interest may influence the stock’s short‑term trajectory.